Clinical Trial Update: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab [Phase 1]

View source ↗

Summary

This Phase 1 update describes adverse events and changes in disease state observed in pediatric participants and young adults (ages 18-25) with relapsed/refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Genmab | Conditions: Non-hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING